MetaCap

Traws Pharma Insider Trades

NASDAQ: TRAWHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.4452-0.0351 (-7.31%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

After hours: 0.447 +0.40%

Last 12 months

Purchases
1 · $998.21K
Sales
0 · $0
Shares bought / sold
597.73K / 0
Net activity
Net buying $998,207

Traws Pharma insider activity

Over the last 12 months, Traws Pharma insiders reported 11 transactions on SEC Form 4: 1 open-market purchase and 0 sales. Insiders bought $998,207 and sold $0 worth of stock, for net insider buying of $998,207. The most recent filing shows ORBIMED ADVISORS LLC & OrbiMed Capital GP VIII LLC (10% Owner) buying 597,729 shares at $1.67 on Apr 16, 2026.

Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put TRAW's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

TRAW insider transactions

Traws Pharma insider transactions
DateInsiderTypeSharesValueFiling
Apr 16, 2026ORBIMED ADVISORS LLC & OrbiMed Capital GP VIII LLC10% OwnerBuy597,729$998.21KForm 4
Dec 12, 2025Redfield RobertChief Medical OfficerAward16,419—Form 4
Dec 12, 2025STOVER JACK EDirectorAward6,157—Form 4
Dec 12, 2025Shoemaker Mary TeresaDirectorAward6,157—Form 4
Dec 12, 2025Savchuk NikolayChief Operating OfficerAward16,419—Form 4
Dec 12, 2025CAUTREELS WERNERDirectorAward4,874—Form 4
Dec 12, 2025Pauza Charles DavidChief Science Officer VirologyAward18,471—Form 4
Dec 12, 2025Dukes Iain D.Chief Executive OfficerAward36,943—Form 4
Dec 12, 2025Clarke TraffordDirectorAward6,157—Form 4
Dec 12, 2025Leaman John HaroldDirectorAward4,058—Form 4
Dec 12, 2025Parker Charles NolanChief Financial OfficerAward15,393—Form 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related